


TESTING CRITERIA FOR PROSTATE CANCER SUSCEPTIBILITY GENES (Genes such as *ATM*, *BRCA1*, *BRCA2*, *CHEK2*, *HOXB13*,^{bb} and *TP53*) ([GENE-A](#))^{a,cc,dd}

Testing is clinically indicated in the following scenarios:

- See General Tumor Criteria on [CRIT-1](#).
- Personal history of prostate cancer at any age with:
 - ▶ Metastatic^p (Stage IVB) or node-positive (Stage IVA) prostate cancer
 - ▶ Very high-risk or high-risk disease (See Initial Risk Stratification and Staging Workup [PROS-2] - [NCCN Guidelines for Prostate Cancer](#))
 - ▶ Ancestry: Ashkenazi Jewish
 - ▶ Family history
 - ◇ ≥1 close blood relative^o with ANY:
 - breast cancer at age ≤50 y
 - male breast cancer
 - ovarian cancer
 - pancreatic cancer
 - metastatic,^p node positive, or very high-risk or high-risk prostate cancer
 - ◇ ≥3 close blood relatives^o with prostate cancer (any grade) and/or breast cancer on the same side of the family including the patient with prostate cancer
 - ◇ For additional family history considerations, see [NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric](#)
- Family history criteria: unaffected; or affected but does not meet criteria above
 - ◇ Individual with a first-degree blood relative meeting any of the criteria listed above (except unaffected individuals whose relatives meet criteria only for systemic therapy decision-making)^q



Testing *may be* considered in the following scenario:

- Personal history of prostate cancer ≤55 y^{ee} not meeting any of the above criteria
- Personal history of prostate cancer with intermediate-risk prostate cancer with intraductal/cirbriform histology (see Initial Risk Stratification and Staging Workup in [NCCN Guidelines for Prostate Cancer](#)) at any age

Refer for genetic testing in the following scenario:

- Biochemical recurrence
 - ▶ For this heterogeneous disease state, refer for genetic testing if: 1) Very high-risk or high-risk disease at diagnosis (see above), 2) family history of cancer criteria met, or if (and at time of) progression to metastatic disease

Note: All recommendations are category 2A unless otherwise indicated.

Footnotes on [CRIT-6A](#)